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Outcomes and predictive factors after cataract surgery in patients with neovascular 
age-related macular degeneration. The Fight Retinal Blindness! Project 
Purpose: To evaluate outcomes and predictive factors of visual acuity (VA) change after 
cataract surgery in patients being treated for neovascular age-related macular degeneration 
(nAMD).  
Design: Retrospective, matched case-control study.  
Methods: We studied eyes undergoing cataract surgery that had been tracked since they 
first started treatment for nAMD. These eyes were compared with a cohort of unoperated 
phakic eyes being treated for nAMD (three per case) matched for treatment duration before 
cataract surgery, baseline VA, age and length of follow-up.   
Results: We included 124 patients that had cataract surgery and 372 matched controls. The 
mean (95% CI) VA gained was 10.6 letters (7.8, 13.2; P < 0.001) 12 months following 
surgery; 26.0% had gained ≥ 3 lines and 1.6% had lost ≥ 3 lines of VA. Visual acuity (mean 
[SD]) 12 months after surgery was higher in eyes that had cataract extraction compared with 
controls (65.8 [17.1] vs. 61.3 [20.8] letters respectively, P = 0.018). The proportion of visits 
where the choroidal neovascular (CNV) lesion was graded active and the mean number of 
injections were similar before and after surgery (P = 0.506 and P = 0.316, respectively), while 
both decreased in the control group, suggesting that surgery modestly increased the level of 
activity of the CNV lesion. Mean [SD] VA prior to surgery was lower in eyes that gained ≥15 
letters compared with eyes that gained 0-14 letters (40.2 [21.4] vs. 62.1 [15.1], P < 0.001). 
Patients undergoing cataract surgery within the first 6 months of anti-VEGF therapy were 
more likely to lose rather than gain vision (20.8% lost vision vs. 12.8% and 4.4% gaining ≥15 
or 0-14 letters respectively, P = 0.023). Age, receiving an injection at least 2 weeks before 
surgery, and the CNV lesion type had no discernible association with VA outcomes.  
Conclusions: We found evidence of a modest effect of cataract surgery on CNV lesion 
activity in eyes being treated for nAMD. Despite this, visual outcomes were reassuringly 
good. Cataract surgery within 6 months of starting treatment for nAMD should be avoided if 
possible.  
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Introduction 1 
Cataract and age-related macular degeneration (AMD), common causes of reduced 2 
vision, often occur together in elderly people. The prevalence of late AMD, including 3 
neovascular AMD (nAMD) or geographic atrophy, and cataract in the same eye after 4 
80 years of age in the USA has been estimated at 12% and 68%, respectively.1,2  5 
A recent Cochrane collaboration report could not draw reliable conclusions from the 6 
available data on whether cataract surgery was beneficial or harmful in people with 7 
dry AMD. Although cataract surgery has been reported to provide better visual 8 
outcomes in eyes with AMD 6 months after surgery compared with eyes that were 9 
observed, it is unclear whether the timing of surgery in relation to commencement of 10 
treatment for AMD influences long-term outcomes.3  11 
Visual acuity (VA) improvement after cataract surgery was less in patients with 12 
nAMD than in patients without retinal disease in the Age-Related Eye Disease 13 
Study.4 A history of intravitreal injections (IVT) may be a risk factor for complications 14 
of cataract surgery, including intra-operative posterior capsule rupture 5 and post-15 
operative endophthalmitis.6 Cataract surgery may increase the risk of progression to 16 
choroidal neovascularization (CNV) in eyes with intermediate AMD;7 it may also 17 
activate existing CNV through inflammatory mediators released at the time of 18 
surgery. 19 
Data on how cataract surgery influences the course of treatment of patients with 20 
nAMD receiving intravitreal vascular endothelial growth factor (VEGF) inhibitors are 21 
encouraging.8–14 However, many of the reports on cataract surgery outcomes in eyes 22 
with nAMD lack a control group, making it difficult to estimate the effect of cataract 23 
surgery on injection frequency or lesion activity post cataract surgery.  24 
The aim of this study was to evaluate the long-term change in VA after cataract 25 
surgery in nAMD and to compare outcomes with a control group matched for similar 26 
baseline characteristics. The secondary objective was to evaluate the CNV lesion 27 
activity and number of anti-VEGF injections before and after cataract surgery. We 28 
also assessed factors that predicted VA outcomes.  29 
 30 
Methods 31 
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This study followed the STROBE checklist items for reporting observational data.15  1 
Study Design 2 
Retrospective, matched case-control analysis performed of data from a prospectively 3 
designed observational database study.  4 
Setting 5 
Data were obtained from the Fight Retinal Blindness! (FRB!) observational database 6 
which tracks outcomes of nAMD and is compliant with the International Consortium 7 
for Healthcare Outcome Measures (ICHOM) macular degeneration standard set.16 8 
Ethics approval was obtained from the Human Research Ethics Committees of the 9 
Royal Victorian Eye and Ear Hospital, the Royal Australian and New Zealand 10 
College of Ophthalmologists, the University of Sydney, and the Cantonal Ethics 11 
Committee Zurich, Switzerland. This study adhered to the tenets of the Declaration 12 
of Helsinki. This study included patients from Australia, New Zealand and 13 
Switzerland.  14 
Data Sources/Measurements 15 
Details of the FRB! database have been published elsewhere.17 Briefly, data were 16 
obtained from each clinical visit, including: the number of letters read on a logarithm 17 
of the minimum angle of resolution (LogMAR) VA Chart (best of uncorrected, 18 
corrected with the current spectacle or according to the refraction, or pinhole); 19 
treatment given, if any; lesion activity (lesions were graded at each visit as active “if 20 
there was intraretinal or subretinal fluid attributable to leak from choroidal 21 
neovascularisation lesion or fresh hemorrhage”); additional procedures including 22 
cataract surgery; ocular adverse events. Lesion size (greatest linear dimension), 23 
lesion type and prior treatment, if any, were recorded during the baseline visit (when 24 
intravitreal therapy for nAMD was started). Treatment decisions, including drug 25 
choice and treatment regimen, were at the discretion of the treatment physician, 26 
thereby reflecting routine clinical practice.  27 
Participants 28 
Treatment-naïve phakic eyes with nAMD tracked by the FRB! registry commencing 29 
anti-VEGF therapy between Jan. 1, 2006 and May. 7, 2014 and undergoing cataract 30 
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surgery were considered for this analysis. Analysis of outcomes also required that 1 
eyes have at least 12 months of follow-up prior to and following cataract surgery. 2 
A cohort of phakic eyes from the FRB! database that did not undergo cataract 3 
surgery was used to assess the effect of cataract surgery on the course of nAMD. 4 
This cohort consisted of three phakic controls per case matched on the following 5 
characteristics: treatment duration before cataract surgery, baseline VA and baseline 6 
age and length of follow-up. The controls had no history of cataract surgery and no 7 
surgery during the study period. Matched controls were only identified for cases that 8 
had at least 12 months of follow-up prior to and following cataract surgery to 9 
compare visual outcomes before and after surgery. 10 
Outcomes 11 
The primary outcome was the change in VA 12 months following cataract surgery. 12 
We also analyzed the proportion of eyes that gained ≥15 or lost ≥15 letters from pre-13 
operative VA.  14 
Secondary outcomes were the proportion of visits where the CNV lesion was graded 15 
active as well as the number of anti-VEGF injections.  16 
Visual acuity and CNV lesion activity were assessed 12 months before vs. 12 17 
months after surgery. The pre-operative VA was defined as VA recorded at the visit 18 
immediately prior to cataract surgery. 19 
Predictive factors were assessed by comparing baseline characteristics of patients 20 
(at presentation for nAMD) classified into 3 groups: those showing a decrease in VA; 21 
those displaying a change in LogMAR letter score between 0 to 15; and those who 22 
achieved an increase in VA ≥15 letters. Variables considered in the analyses of 23 
predictive factors included the baseline age, lesion type, the time to cataract surgery, 24 
whether an injection in the 2 weeks before the surgery, the interval between the last 25 
IVT and cataract surgery and lesion activity prior to cataract surgery. 26 
Statistical Analyses 27 
For bilateral patients, the first eye, or the worse eye when both eyes presented 28 
simultaneously, was used.  29 
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Descriptive data were summarized using the mean (standard deviation [SD]), 1 
median (quantiles [Q1, Q3]) and percentages where appropriate. Within-group 2 
change in VA after cataract surgery was analyzed using paired t-tests.  3 
The proportion of visits where CNV was active before and after cataract surgery was 4 
compared using logistic regression for both within-group and between-group 5 
comparisons between cases and matched controls with eye included as a random 6 
effect for repeated visits. Between-group comparison of VA between cases and 7 
matched controls was performed using mixed-effects models. The number of 8 
injections before and after surgery was compared using Poisson regression for 9 
within-group and between-group analyses with an offset for log days’ follow-up. 10 
Between-group logistic, mixed-effects and Poisson regression models also included 11 
an identifier variable to indicate matched patients as a nested random effect.  12 
Comparisons of characteristics between eyes categorized by change from pre-13 
operative VA (gain ≥15 letters, gain 0-14 letters, and loss ≥1 letter) was performed 14 
by several univariable models using ANOVA, Kruskal-Wallis or log-rank tests, 15 
followed by pairwise comparisons using Holm-Bonferroni adjustments where 16 
appropriate.  17 
All analyses were conducted using R V.3.3.2 with the lme4 package (V 1.1-12) for 18 
logistic, mixed-effects and Poisson regression 18–20and the MatchIt package (V 3.0.1) 19 
to identify matched controls. 21 20 
Results 21 
Study Population (Table 1) 22 
We identified 302 eyes from 273 patients from the FRB! database that underwent 23 
cataract surgery in the registry; considering only the first (or worse) eye in bilateral 24 
patients, 162 eyes of 162 patients had at least 12 months of follow-up that was 25 
required for the predictive analysis with no limit to the time prior to surgery; Their 26 
median (IQR) time until cataract surgery was 28 (12-52) months. The median (Q1, 27 
Q3) interval between the last IVT and cataract surgery was 61 (36, 115) days. Of 28 
these eyes, 124 also had the 12 months of follow-up prior to and following surgery 29 
that was required to compare the frequency of injections and lesion activity before 30 
vs. after the cataract surgery. Therefore, the primary outcome analysis was 31 
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performed on 124 eyes of 124 patients (with 372 matched controls) and the 1 
predictive factor analysis on 162 eyes of 162 patients.  2 
Demographic characteristics are summarized in Table 1. Mean (SD) VA at baseline 3 
(time of first injection for nAMD) was 60.4 (14.5) letters and VA prior to cataract 4 
surgery was 55.2 (20.1) letters.  5 
Visual Acuity Outcomes after Cataract Surgery (Table 2, Figure 1) 6 
Eyes undergoing cataract surgery gained a mean of 10.6 letters (95%CI: 7.8, 13.2; P 7 
< 0.001) 12 months following the surgery compared with the last pre-operative visit; 8 
26.0% gained ≥ 3 lines and 1.6% lost ≥ 3 lines (Table 2 and Figure 1). Cataract 9 
surgery patients also had higher mean [SD] VA 12 months after surgery compared 10 
with their matched controls during the same time period (65.8 [17.1] vs. 61.3 [20.8] 11 
letters respectively, P = 0.018).  12 
Effect of Cataract Surgery on Lesion Activity and Treatment Patterns (Table 3) 13 
The proportion of visits where the CNV lesion was graded as active remained 14 
constant before and after cataract surgery (51.7% vs. 52.2%, P = 0.506), and 15 
decreased in the control group during the same period after starting anti-VEGF 16 
therapy (47.9% vs. 43.0%, P < 0.001; Table 3). The median treatment interval [Q1, 17 
Q3] when the CNV lesion was graded as active was the same before and after the 18 
surgery (53 [42, 84] vs. 51 [41, 81] days, P = 0.665) whereas it increased for 19 
matched controls during the same period (56 [46, 77] vs. 60 [48, 88] days, P < 0.001; 20 
Table 3). The mean [SD] number of injections was similar in the 12 months before 21 
vs. after cataract surgery (5.4 [3.3] vs. 5.4 [3.3] injections P = 0.316) in the operated 22 
group and decreased in the control group during the same period after starting anti-23 
VEGF therapy (5.4 [2.8] vs. 4.9 [2.9] injections P = 0.316; Table 3). 24 
Analysis of predictive factors for VA change after cataract surgery (table 4) 25 
The mean (SD) VA prior to surgery was lower in eyes that gained ≥15 letters 26 
compared with eyes that gained 0-14 letters (40.2 [21.4] vs. 62.1 [14.9], P <0.001). 27 
Cataract surgery in the 6 first months of anti-VEGF therapy was associated with a 28 
higher risk of vision loss (P = 0.023). Other factors including age (P = 0.154), lesion 29 
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activity prior the surgery (P = 0.858), an injection at least 2 weeks prior to surgery (P 1 
= 0.862), and the lesion type (P = 0.261), had no discernible predictive effect.  2 
Discussion 3 
The prospective design of the FRB! registry allowed us to assess the effect of 4 
cataract surgery on long-term VA outcomes and on the course of nAMD, including 5 
CNV lesion activity and number of anti-VEGF injections before and after surgery. 6 
There was a mean gain in VA of around 10 letters (2 lines) and 26% of eyes had 7 
gained more than 3 lines of VA 12 months after surgery. Patients undergoing 8 
cataract surgery had better VA, were more likely to have active lesions and more 9 
anti-VEGF injections than their matched unoperated controls in the 12-months 10 
following surgery. We found that VA outcomes were associated with the level of 11 
vision immediately prior to surgery and that cataract surgery performed within 6 12 
months of starting anti-VEGF therapy was associated with an increased risk of vision 13 
loss.  14 
Lee et al. suggested cataract surgery should not be performed in the first 12 months 15 
of anti-VEGF therapy.13 The average time from the first injection to cataract surgery 16 
was 14 months in the post-hoc analysis of ANCHOR (Anti-VEGF Antibody for the 17 
Treatment of Predominantly Classic Choroidal Neovascularization in AMD) and 18 
MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in 19 
the Treatment of Neovascular AMD) trials.10  We found patients that had cataract 20 
surgery within 6 months of initiating anti-VEGF therapy were more likely to lose 21 
vision. Since most eyes in the FRB! database were likely to be on treat-and-extend,22 22 
it is possible that only after the first 6 months after commencing anti-VEGF therapy 23 
were lesions sufficiently controlled to allow for an increase in VA and a reduced risk 24 
to lose vision.  25 
Previous studies have generally reported improvements in mean VA in eyes 26 
receiving IVT for nAMD that had their cataract removed. The VA improvement was 2  27 
lines from the pre-operative VA 3 months after surgery in a retrospective analysis of 28 
the ANCHOR and MARINA trials.10 A VA improvement of 7 letters at 6 months after 29 
cataract surgery was observed in another retrospective study of 89 eyes.14 Lee et al. 30 
reported that 39% of 39 eyes gained more than 3  lines of VA, 54% remained stable, 31 
but 7% had lost more than three lines 6 months after the cataract surgery.13 Eyes 32 
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with mild AMD undergoing cataract surgery gained a mean of 6 letters, eyes with 1 
moderate AMD gained 4 letters, and eyes with advanced AMD gained 2 letters in the 2 
Age-Related Eye Disease Study.4 A mean improvement of 10 letters (2 lines) was 3 
observed in the present study 12 months after cataract surgery with 27.5% of eyes 4 
gaining more than 3 lines and 2.2% of eyes losing more than 3 lines. Unsurprisingly 5 
our analysis of predictive factors showed patients with worse vision had more 6 
improvement after cataract surgery. Several studies have reported similar trends 7 
whereby eyes with worse vision at presentation for nAMD tend to have greater 8 
improvement in VA as there is a limit to how much eyes with better vision can 9 
improve further. It has been speculated that intravitreal injections may work better in 10 
eyes with a posterior vitreous detachment,23 which is often induced by cataract 11 
extraction.24  12 
It has been proposed that the level of activity of the CNV in eyes on treatment for 13 
nAMD should be considered before performing cataract surgery.13 This parameter 14 
was not available in the post-hoc analysis of MARINA and ANCHOR trials, but 15 
presence of ongoing exudation may explain why cataract surgery was not performed 16 
in any of the sham-treated patients in the MARINA trial.10 In the present study, the 17 
proportion of visits where the CNV lesion was graded active was similar before and 18 
after the cataract operation while lesion activity decreased in the control group during 19 
the same period after starting anti-VEGF therapy. Although it did not increase, the 20 
relatively higher CNV activity state after cataract extraction compared with controls 21 
may be related to the release of inflammatory mediators associated with cataract 22 
surgery. Such mediators are the likely cause of post-surgical cystoid macular edema, 23 
the commonest macular complication of cataract surgery.25 24 
The frequency of anti-VEGF injections did not change 6 months before vs. 6 months 25 
after cataract surgery in the studies conducted by Kessel et al.14 and Grixti et al.12 26 
The authors of these two studies concluded cataract surgery did not influence the 27 
course of nAMD but neither study compared its outcomes with a control group of 28 
unoperated eyes. We also did not observe any difference in the number of anti-29 
VEGF injections in the 12 months before vs. after the surgery. However, the number 30 
of injections decreased in the control group in the same period after starting anti-31 
VEGF therapy, suggesting that the requirement for treatment was increased 32 
somewhat in the postoperative period. It is possible that anti-VEGF agents last 33 
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longer in phakic eyes, however, it has been reported that there was no difference in 1 
visual and anatomical outcomes between phakic and pseudophakic eyes being 2 
treated for nAMD.26–28  3 
It has been proposed that IVT with a VEGF inhibitor should be considered during 4 
cataract surgery to reduce the risk of activating the CNV lesion.8,9 We did not 5 
observe any relationship between a IVT performed in the 2 weeks before the 6 
cataract surgery and VA outcomes. A preoperative exudation-free period may be 7 
another important parameter when considering cataract surgery.13  8 
 9 
Several limitations to the present study should be noted. Details were not available 10 
on the rationale for surgery, timing of the surgery, the grade of cataract or the type, 11 
duration and complications of cataract surgery performed. It was therefore possible 12 
that there was selection bias in our study as the decision to operate was purely at 13 
the discretion of the treating physicians. Nor was information available on the type 14 
and duration of topical anti-inflammatory drops used after surgery, which may have 15 
influenced the degree of activity of the CNV lesion. Also, it may occasionally be 16 
challenging to differentiate pseudophakic cystoid macular edema from CNV 17 
recurrence in clinical practice. Our results are likely, however, to be applicable to a 18 
broader category of patients with nAMD than have been studied in randomized 19 
clinical trials.  20 
The main strengths of the present study are the documentation of VA from when 21 
eyes first started treatment, inclusion of a matched control group and a detailed 22 
analysis of the period 12-months prior to cataract surgery and the 12-month 23 
outcomes after cataract surgery.  Observational data may be the best way to study 24 
the safety and efficacy of cataract surgery in this context since there may be ethical 25 
issues with randomized clinical trials which would require randomization of a group 26 
with clinically significant cataract to observation only.  27 
This study found evidence of a modest effect of cataract surgery on CNV lesion 28 
activity in eyes being treated for nAMD. Despite this, visual outcomes were 29 
reassuringly good. Cataract surgery within 6 months of starting treatment for nAMD 30 
should be avoided if possible.  31 
 32 
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Figure legends 1 
Figure 1. Locally weighted scatterplot smoothing (LOESS) regression curves of 2 
mean visual acuity 12 months before vs. 12 months after the cataract surgery for 3 
cases and matched controls. 4 
 5 
 6 
 7 
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Table 1. Demographic characteristics of patients with neovascular age-related 
macular degeneration undergoing cataract surgery and phakic controls.  
 Cataract Surgery 
Patients 
N=124 
Matched phakic 
Controls* 
N=372 
Eyes 124 372 
Females, % 61.3% 65.6% 
Baseline Age, Mean 
Years (SD) 
77.8 (6.3) 77.9 (6.3) 
Baseline VA , Mean 
Letters (SD) 
60.4 (14.5) 60.8 (13.6) 
Baseline Lesion Size, 
Median µm (Q1, Q3) 
2525 (1688, 3214) 2375 (1216, 3463) 
Lesion Type, %   
Occult 56.5% 51.3% 
Minimally Classic 10.5% 14.8% 
Predominantly Classic 20.2% 20.2% 
Other 11.3% 4.0% 
Not Recorded 1.6% 9.7% 
Abbreviations: VA: Visual acuity in number of letters read on a logarithm of the 
minimum angle of resolution (LogMAR) VA Chart; SD: Standard Deviation; 95% CI: 
95% Confidence Interval; Q1, Q3: 25th and 75th percentiles 
*Three controls per case were matched on the following characteristics: time duration 
before cataract surgery, baseline visual acuity, baseline age, and length of follow-up. 
The controls had no history of cataract surgery and no surgery during the study 
period.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2. Visual acuity outcomes 12 months after cataract surgery in patients 
with neovascular age-related macular degeneration 
 Cataract 
Surgery 
Patients 
Matched 
phakic 
Controls 
 (N=124) (N=372) 
VA at Baseline, Mean Letters (SD) 60.4 (14.5) 60.8 (13.6) 
Time Until Surgery, Median Months (Q1, Q3) 34 (22, 56) - 
VA prior to Surgery, Mean Letters (SD)* 55.2 (20.1) 63.1 (19.5) 
VA 12 months after cataract surgery, 
endpoint for VA evaluation, Mean Letters (SD)** 65.8 (17.1) 61.3 (20.8) 
Proportion of eyes with ∆VA 12 months from 
pre-op VA, % 
  
Loss ≥15 Letters 1.6% 8.9% 
Loss 1-14 Letters 11.4% 42.3% 
Gain 0-14 Letters 61.0% 44.7% 
Gain ≥15 Letters 26.0% 4.0% 
Abbreviations: VA: Visual acuity in number of letters read on a logarithm of the 
minimum angle of resolution (LogMAR) VA Chart; SD: Standard Deviation; Q1, Q3: 
25th and 75th percentiles 
*Phakic controls were matched on time duration before cataract surgery to assess 
the final endpoint (VA 12 months after cataract surgery) fairly between cases and 
controls. VA prior to surgery in the phakic neovascular age-related macular 
degeneration control group corresponded to the same time period as their matched 
cases i.e. a median time of 34 (22-56) months after commencement treatment for 
neovascular age-related macular degeneration. 
** The mean (SD) VA 12 months following the surgery was better in cases than in 
unoperated phakic controls (P = 0.018). 
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Table 3. Comparison of treatment and lesion activity patterns before and after 
surgery and between cases and matched phakic controls in patients with 
neovascular age-related macular degeneration 
 12 Months P-value** 
 Before Surgery After Surgery 
Injections, Mean 
(SD) 
   
Cases 5.4 (3.3) 5.4 (3.3) 0.316 
Controls* 5.4 (2.8) 4.9 (2.9) <0.001 
P-value** 0.703 0.014  
Proportion Visits 
CNV Lesion Active, 
% 
   
Cases 51.7% 52.2% 0.506 
Controls* 47.9% 43.0% <0.001 
P-value** 0.674 0.079  
Treatment Interval 
CNV lesion Active, 
Median Days (Q1, 
Q3) 
   
Cases 53 (42, 84) 51 (41, 81) 0.665 
Controls* 56 (46, 77) 60 (48, 88) <0.001 
P-value** 0.242 0.009  
Abbreviations: CNV: Choroidal neovascular membrane; Q1, Q3: 25th and 75th 
percentiles 
*Three controls per case were matched on the following characteristics: time duration 
before cataract surgery, baseline visual acuity, baseline age and length of follow-up. 
** P-values in columns are comparing within-group changes before and after surgery 
and p-values in rows are comparing between cases and controls. 
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The proportion of visits where the CNV lesion was graded as active and mean 
injection frequency in the 12 months following the cataract surgery was higher in 
eyes undergoing cataract surgery than in matched controls.  
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Table 4: Predictive factor for 12 months visual acuity change after cataract 
surgery (from pre-operative) in patients with neovascular age-related macular 
degeneration 
12 months’ visual acuity change Gained ≥15 
Letters 
Gain 0-14 
Letters 
Lost ≥1 
Letter 
P-value** 
Eyes 47 91 24  
Baseline Age, Mean Years (SD) 80.1 (6.4) 78.1 (6.8) 90.2 (6.1) 0.154 
VA Prior to Surgery, Mean Letters 
(SD) 
40.2 (21.4) 62.1 (14.9) 53.5 (20.2) <0.001 
Lesion Type, % 
    
Occult 68.1% 56.0% 50.0% 0.261 
Minimally Classic 10.6% 11.0% 12.5%  
Predominantly Classic 8.5% 22.0% 20.8%  
Other 6.4% 11.0% 16.7%  
Not Recorded 6.4% 0.0% 0.0%  
Time Until Surgery, Median 
Months (Q1, Q3)* 
18.1 (10.3, 
43.5) 
29.2 (14.2, 
47.2) 
19.7 (10.3, 
31.1) 
0.332 
<6 months between the beginning 
of anti-VEGF and cataract 
extraction, n (%) 
6 (12.8%) 4 (4.4%) 5 (20.8%) 0.023 
>6 months between the beginning 
of anti-VEGF and cataract 
extraction, n (%) 
41 (87.2%) 87 (95.6%) 19 (79.2%)  
Lesion Activity in the Visit 
Immediately Prior to the Surgery, 
n (%) 
    
Active 21 (44.7%) 36 (39.6%) 10 (41.7%) 0.858 
Inactive 26 (55.3%) 55 (60.4%) 14 (58.3%)  
Prophylactic Injection in the 2 
Weeks Before the Surgery, n (%) 
    
Yes 1 (2.1%) 4 (4.4%) 1 (4.2%) 0.862 
No 46 (97.9%) 87 (95.6%) 23 (95.8%)  
Interval Between the Last Injection 
and Cataract Surgery, Median 
Days (Q1, Q3) 
56 (35, 137) 49 (35, 91) 53 (29, 96) 0.509 
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Abbreviations: VA: Visual acuity in number of letters read on a logarithm of the 
minimum angle of resolution (LogMAR) VA Chart; SD: Standard Deviation; Q1, Q3: 
25th and 75th percentiles; ANOVA (analysis of variance) 
*No restriction of time to surgery but at least 12 months of follow-up post-surgery and 
only the first or worse eye in bilateral patients (n = 162 eyes). 
** P-values are global tests comparing characteristics between eyes that gained ≥15 
letters, gained 0-14 letters, or lost ≥1 letter using ANOVA, Kruskal-Wallis or log-rank 
tests where appropriate. 
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